Free tool
FAERS Monitor: Viokace
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 022542 or its brand name (Viokace, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.
Reports
2,537
Serious
2,257
89% of reports
Hospitalization
1,448
Death reported
286
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea256
- nausea158
- dyspnoea135
- fatigue133
- off label use131
- vomiting126
- abdominal pain118
- asthenia118
- pyrexia115
- pain108
- weight decreased107
- drug ineffective98
- pneumonia94
- acute kidney injury88
- dizziness86
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 16 |
| 2006 | 10 |
| 2007 | 13 |
| 2008 | 12 |
| 2009 | 21 |
| 2010 | 45 |
| 2011 | 49 |
| 2012 | 53 |
| 2013 | 66 |
| 2014 | 56 |
| 2015 | 93 |
| 2016 | 98 |
| 2017 | 103 |
| 2018 | 118 |
| 2019 | 141 |
| 2020 | 170 |
| 2021 | 235 |
| 2022 | 271 |
| 2023 | 260 |
| 2024 | 276 |
| 2025 | 269 |
| 2026 | 140 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,622 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 88 | 4.8 | 3.9 | 260 |
| abdominal painSignal | 118 | 4.2 | 3.5 | 288 |
| diarrhoeaSignal | 256 | 3.3 | 2.9 | 418 |
| weight decreasedSignal | 107 | 3.2 | 2.6 | 160 |
| pyrexiaSignal | 115 | 2.8 | 2.3 | 129 |
| astheniaSignal | 118 | 2.6 | 2.2 | 117 |
| pneumoniaSignal | 94 | 2.4 | 2.0 | 77 |
| vomitingSignal | 126 | 2.2 | 1.9 | 85 |
| dyspnoea | 135 | 2.0 | 1.7 | 66 |
| nausea | 158 | 1.7 | 1.4 | 42 |
| pain | 108 | 1.5 | 1.2 | 16 |
| dizziness | 86 | 1.4 | 1.2 | 11 |
| fatigue | 133 | 1.4 | 1.2 | 16 |
| off label use | 131 | 1.2 | 1.0 | 6 |
| drug ineffective | 98 | 0.6 | 0.5 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.